Related Experiment Video
Updated: Jul 6, 2025
06:09
Quantification of Tumor Cell Adhesion in Lymph Node Cryosections
Published on: February 9, 2020
12.1K
LCN2: Versatile players in breast cancer
Yuxiang Bao1, Zhongliang Yan1, Nianmei Shi2
1Department of General Surgery, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563099, China.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 3, 2024
Summary
Lipocalin 2 (LCN2) is elevated in breast cancer (BC), impacting cell growth and treatment resistance. This review explores LCN2
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Lipocalin 2 (LCN2) is a protein secreted by immune cells like neutrophils and macrophages.
- It plays roles in ligand transport, immune regulation, iron homeostasis, and epithelial cell differentiation.
- LCN2 expression is often increased in various diseases and cancers.
Purpose of the Study:
- To review the role of Lipocalin 2 (LCN2) in the development and progression of breast cancer (BC).
- To highlight LCN2 as a potential therapeutic target for BC.
Main Methods:
- Literature review of studies on LCN2 and breast cancer.
- Analysis of LCN2's involvement in BC cell proliferation, apoptosis, invasion, migration, angiogenesis, and immune response.
Main Results:
- Elevated LCN2 levels are associated with increased BC cell proliferation, invasion, and migration.
- LCN2 influences angiogenesis, immune regulation, and chemotherapy resistance in breast cancer.
- LCN2 expression correlates with BC prognosis.
Conclusions:
- Lipocalin 2 (LCN2) is a significant factor in breast cancer progression and therapeutic outcomes.
- Targeting LCN2 presents a promising strategy for novel BC treatments.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:53Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K